Angela Sheu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Angela Sheu has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Jacqueline R. Center
Skeletal Diseases Program Garvan Institute of Medical Research Sydney NSW Australia
5 shared publications- Chris White
Department of Endocrinology Prince of Wales Hospital Sydney New South Wales Australia
4 shared publications - Dana Bliuc
Garvan Institute of Medical Research Darlinghurst New South Wales Australia
4 shared publications - Brenda Ta
Faculty of Medicine and Health University of Sydney Sydney New South Wales Australia
3 shared publications Christopher P. White
School of Clinical Medicine, Prince of Wales Clinical Campus, Faculty of Medicine and Health UNSW Sydney Sydney NSW Australia
3 shared publications- Jacqueline R. Center
Garvan Institute of Medical Research, Sydney, Australia
3 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by Wiley in Internal Medicine Journal
- Vol. 56 (9) , 1500-1509
Hypophosphataemia following iron infusion: a narrative review of an increasingly recognised complication
Parenteral iron is widely prescribed by medical practitioners, with more than 600 000 outpatient prescriptions dispensed in 2025 through the Australian Pharmaceutical Benefits Scheme. While intravenous iron has transformed the management of iron deficiency, hypophosphataemia is now recognised as a common complication, with incidences reported as high as 92% depending on formulation. Although most cases are mild and transient, vulnerable patient groups may develop profound and symptomatic hypophosphataemia, sometimes requiring hospitalisation and intravenous phosphate replacement. The clinical spectrum ranges from subtle biochemical abnormalities to lethargy, weakness and myalgias and, rarely, severe manifestations including muscle weakness, osteomalacia, myopathy, arrhythmias and cardiomyopathy. This narrative review presents five illustrative cases, highlighting the varied presentations of iron‐induced hypophosphataemia and potential patient groups at high risk. To address this growing challenge, we present an institutionally endorsed management pathway based on our review of the literature and current practice after multidisciplinary consultation. The algorithm emphasises early recognition of high‐risk patients, primary prevention by using formulations of iron associated with the lowest risk of hypophosphataemia, timely identification of symptomatic hypophosphataemia and coordinated correction of concurrent electrolyte disturbances, with the aim of improving patient safety and outcomes.
- 30 July 2026
- Published by Wiley in Internal Medicine Journal
- Vol. 56 (9) , 1500-1509
Open AccessHypophosphataemia following iron infusion: a narrative review of an increasingly recognised complication
Parenteral iron is widely prescribed by medical practitioners, with more than 600 000 outpatient prescriptions dispensed in 2025 through the Australian Pharmaceutical Benefits Scheme. While intravenous iron has transformed the management of iron deficiency, hypophosphataemia is now recognised as a common complication, with incidences reported as high as 92% depending on formulation. Although most cases are mild and transient, vulnerable patient groups may develop profound and symptomatic hypophosphataemia, sometimes requiring hospitalisation and intravenous phosphate replacement. The clinical spectrum ranges from subtle biochemical abnormalities to lethargy, weakness and myalgias and, rarely, severe manifestations including muscle weakness, osteomalacia, myopathy, arrhythmias and cardiomyopathy. This narrative review presents five illustrative cases, highlighting the varied presentations of iron‐induced hypophosphataemia and potential patient groups at high risk. To address this growing challenge, we present an institutionally endorsed management pathway based on our review of the literature and current practice after multidisciplinary consultation. The algorithm emphasises early recognition of high‐risk patients, primary prevention by using formulations of iron associated with the lowest risk of hypophosphataemia, timely identification of symptomatic hypophosphataemia and coordinated correction of concurrent electrolyte disturbances, with the aim of improving patient safety and outcomes.
- Open Access
The effect of prior osteoporosis treatment on bone mineral density response to romosozumab
- Open Access
- 3 February 2026
- Published by Elsevier in SSRN Electronic Journal
The effect of prior osteoporosis treatment on bone mineral density response to romosozumab
BackgroundRomosozumab is an osteoanabolic agent with dual anabolic and antiresorptive effects, with substantial benefits on bone mineral density (BMD) and fracture risk reduction. BMD gains are attenuated by prior antiresorptive treatment. This study aimed to compare real-world effects of romosozumab on BMD and bone turnover markers (BTM) according to prior antiresorptive treatment.MethodsWe conducted a retrospective audit of patients who completed 12 months of romosozumab treatment between April 2021 and October 2024 at a tertiary hospital and affiliated clinics. Patients were analysed according to treatment history: treatment-naïve, prior bisphosphonate, or prior denosumab. Primary outcome was percentage change in BMD at the lumbar spine (LS) over 12 months. Secondary outcomes were percentage changes in femoral neck (FN), total hip (TH) BMD and bone turnover markers (procollagen type 1 n-propeptide and c-telopeptide) over 12 months. Between-group differences were assessed using ANCOVA and linear mixed models. Subgroup analyses examined the effect of duration of prior treatment and timing of transition from denosumab on BMD.ResultsSeventy-two patients were included (mean age 72.4 ± 11.9 years; 83% female). 20 patients were treatment naïve, 32 transitioned from bisphosphonates and 20 transitioned from denosumab. Patients in the treatment naïve group were younger, had lower baseline BMD and fracture risk compared to the bisphosphonate or denosumab group. LS BMD gains were significantly greater in treatment-naïve patients compared to those with prior bisphosphonate or denosumab exposure (13.1% vs 8.5% vs 4.4%, p=0.04). There were no significant differences in percentage change for FN or TH BMD across groups. A longer duration of prior antiresorptive therapy and later romosozumab initiation following denosumab were associated with smaller BMD gains. C-terminal teloptide (CTx) levels decreased in both treatment naïve and prior bisphosphate groups but transiently increased in the prior denosumab group before stabilising by 6–12 months.ConclusionIn our real-world cohort, romosozumab effectively increased BMD, particularly in treatment-naïve patients. Duration of prior antiresorptive therapy and timing of transition from denosumab significantly influenced BMD gains. Prospective studies are needed to optimise transition strategies from antiresorptive agents.
- 3 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessThe effect of prior osteoporosis treatment on bone mineral density response to romosozumab
BackgroundRomosozumab is an osteoanabolic agent with dual anabolic and antiresorptive effects, with substantial benefits on bone mineral density (BMD) and fracture risk reduction. BMD gains are attenuated by prior antiresorptive treatment. This study aimed to compare real-world effects of romosozumab on BMD and bone turnover markers (BTM) according to prior antiresorptive treatment.MethodsWe conducted a retrospective audit of patients who completed 12 months of romosozumab treatment between April 2021 and October 2024 at a tertiary hospital and affiliated clinics. Patients were analysed according to treatment history: treatment-naïve, prior bisphosphonate, or prior denosumab. Primary outcome was percentage change in BMD at the lumbar spine (LS) over 12 months. Secondary outcomes were percentage changes in femoral neck (FN), total hip (TH) BMD and bone turnover markers (procollagen type 1 n-propeptide and c-telopeptide) over 12 months. Between-group differences were assessed using ANCOVA and linear mixed models. Subgroup analyses examined the effect of duration of prior treatment and timing of transition from denosumab on BMD.ResultsSeventy-two patients were included (mean age 72.4 ± 11.9 years; 83% female). 20 patients were treatment naïve, 32 transitioned from bisphosphonates and 20 transitioned from denosumab. Patients in the treatment naïve group were younger, had lower baseline BMD and fracture risk compared to the bisphosphonate or denosumab group. LS BMD gains were significantly greater in treatment-naïve patients compared to those with prior bisphosphonate or denosumab exposure (13.1% vs 8.5% vs 4.4%, p=0.04). There were no significant differences in percentage change for FN or TH BMD across groups. A longer duration of prior antiresorptive therapy and later romosozumab initiation following denosumab were associated with smaller BMD gains. C-terminal teloptide (CTx) levels decreased in both treatment naïve and prior bisphosphate groups but transiently increased in the prior denosumab group before stabilising by 6–12 months.ConclusionIn our real-world cohort, romosozumab effectively increased BMD, particularly in treatment-naïve patients. Duration of prior antiresorptive therapy and timing of transition from denosumab significantly influenced BMD gains. Prospective studies are needed to optimise transition strategies from antiresorptive agents.
- Open Access
- 23 May 2024
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 8 (7) , bvae112
Bone Health in Patients With Type 2 Diabetes
The association between type 2 diabetes mellitus (T2DM) and skeletal fragility is complex, with effects on bone at the cellular, molecular, and biomechanical levels. As a result, people with T2DM, compared to those without, are at increased risk of fracture, despite often having preserved bone mineral density (BMD) on dual-energy x-ray absorptiometry (DXA). Maladaptive skeletal loading and changes in bone architecture (particularly cortical porosity and low cortical volumes, the hallmark of diabetic osteopathy) are not apparent on routine DXA. Alternative imaging modalities, including quantitative computed tomography and trabecular bone score, allow for noninvasive visualization of cortical and trabecular compartments and may be useful in identifying those at risk for fractures. Current fracture risk calculators underestimate fracture risk in T2DM, partly due to their reliance on BMD. As a result, individuals with T2DM, who are at high risk of fracture, may be overlooked for commencement of osteoporosis therapy. Rather, management of skeletal health in T2DM should include consideration of treatment initiation at lower BMD thresholds, the use of adjusted fracture risk calculators, and consideration of metabolic and nonskeletal risk factors. Antidiabetic medications have differing effects on the skeleton and treatment choice should consider the bone impacts in those at risk for fracture. T2DM poses a unique challenge when it comes to assessing bone health and fracture risk. This article discusses the clinical burden and presentation of skeletal disease in T2DM. Two clinical cases are presented to illustrate a clinical approach in assessing and managing fracture risk in these patients.
- 23 May 2024
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 8 (7) , bvae112
Open AccessBone Health in Patients With Type 2 Diabetes
The association between type 2 diabetes mellitus (T2DM) and skeletal fragility is complex, with effects on bone at the cellular, molecular, and biomechanical levels. As a result, people with T2DM, compared to those without, are at increased risk of fracture, despite often having preserved bone mineral density (BMD) on dual-energy x-ray absorptiometry (DXA). Maladaptive skeletal loading and changes in bone architecture (particularly cortical porosity and low cortical volumes, the hallmark of diabetic osteopathy) are not apparent on routine DXA. Alternative imaging modalities, including quantitative computed tomography and trabecular bone score, allow for noninvasive visualization of cortical and trabecular compartments and may be useful in identifying those at risk for fractures. Current fracture risk calculators underestimate fracture risk in T2DM, partly due to their reliance on BMD. As a result, individuals with T2DM, who are at high risk of fracture, may be overlooked for commencement of osteoporosis therapy. Rather, management of skeletal health in T2DM should include consideration of treatment initiation at lower BMD thresholds, the use of adjusted fracture risk calculators, and consideration of metabolic and nonskeletal risk factors. Antidiabetic medications have differing effects on the skeleton and treatment choice should consider the bone impacts in those at risk for fracture. T2DM poses a unique challenge when it comes to assessing bone health and fracture risk. This article discusses the clinical burden and presentation of skeletal disease in T2DM. Two clinical cases are presented to illustrate a clinical approach in assessing and managing fracture risk in these patients.
- Open Access
- 18 May 2024
- Published by Springer Nature in Diabetologia
- Vol. 67 (8) , 1493-1506
Bone metabolism in diabetes: a clinician’s guide to understanding the bone–glucose interplay
Skeletal fragility is an increasingly recognised, but poorly understood, complication of both type 1 and type 2 diabetes. Fracture risk varies according to skeletal site and diabetes-related characteristics. Post-fracture outcomes, including mortality risk, are worse in those with diabetes, placing these people at significant risk. Each fracture therefore represents a sentinel event that warrants targeted management. However, diabetes is a very heterogeneous condition with complex interactions between multiple co-existing, and highly correlated, factors that preclude a clear assessment of the independent clinical markers and pathophysiological drivers for diabetic osteopathy. Additionally, fracture risk calculators and routinely used clinical bone measurements generally underestimate fracture risk in people with diabetes. In the absence of dedicated prospective studies including detailed bone and metabolic characteristics, optimal management centres around selecting treatments that minimise skeletal and metabolic harm. This review summarises the clinical landscape of diabetic osteopathy and outlines the interplay between metabolic and skeletal health. The underlying pathophysiology of skeletal fragility in diabetes and a rationale for considering a diabetes-based paradigm in assessing and managing diabetic bone disease will be discussed. Graphical Abstract
- 18 May 2024
- Published by Springer Nature in Diabetologia
- Vol. 67 (8) , 1493-1506
Open AccessBone metabolism in diabetes: a clinician’s guide to understanding the bone–glucose interplay
Skeletal fragility is an increasingly recognised, but poorly understood, complication of both type 1 and type 2 diabetes. Fracture risk varies according to skeletal site and diabetes-related characteristics. Post-fracture outcomes, including mortality risk, are worse in those with diabetes, placing these people at significant risk. Each fracture therefore represents a sentinel event that warrants targeted management. However, diabetes is a very heterogeneous condition with complex interactions between multiple co-existing, and highly correlated, factors that preclude a clear assessment of the independent clinical markers and pathophysiological drivers for diabetic osteopathy. Additionally, fracture risk calculators and routinely used clinical bone measurements generally underestimate fracture risk in people with diabetes. In the absence of dedicated prospective studies including detailed bone and metabolic characteristics, optimal management centres around selecting treatments that minimise skeletal and metabolic harm. This review summarises the clinical landscape of diabetic osteopathy and outlines the interplay between metabolic and skeletal health. The underlying pathophysiology of skeletal fragility in diabetes and a rationale for considering a diabetes-based paradigm in assessing and managing diabetic bone disease will be discussed. Graphical Abstract
- Open Access
- 8 June 2023
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 7 (9) , e10780
Associations of Type 2 Diabetes, Body Composition, and Insulin Resistance with Bone Parameters: The Dubbo Osteoporosis Epidemiology Study
Type 2 diabetes (T2D) may be associated with increased risk of fractures, despite preserved bone mineral density (BMD). Obesity and insulin resistance (IR) may have separate effects on bone turnover and bone strength, which contribute to skeletal fragility. We characterized and assessed the relative associations of obesity, body composition, IR, and T2D on bone turnover markers (BTMs), BMD, and advanced hip analysis (AHA). In this cross‐sectional analysis of Dubbo Osteoporosis Epidemiology Study, 525 (61.3% women) participants were grouped according to T2D, IR (homeostasis model assessment insulin resistance [HOMA‐IR] </≥2.5), and BMI (</≥25 kg/m2): insulin‐sensitive lean (IS‐L), insulin‐sensitive overweight/obese (IS‐O), insulin‐resistant (IR), and T2D. BMD, AHA, and body composition, including visceral adipose tissue (VAT) (on dual‐energy x‐ray absorptiometry scan) and fasting BTMs, were assessed. Analyses performed using Bayesian model averaging and principal component analysis. T2D was associated with low BTMs (by 26%–30% [95% confidence interval [CI] 11%–46%] in women, 35% [95% CI 18%–48%] in men compared to IS‐L), which persisted after adjustment for VAT. BTMs were similar among IR/IS‐O/IS‐L. BMD was similar among T2D/IR/IS‐O; BMD was low only in IS‐L. All groups were similar after adjustment for BMI. Similarly, AHA components were lowest in IS‐L (attenuated following adjustment). On multivariate analysis, T2D was independently associated with BTMs. IR was also associated with C‐terminal telopeptide of type 1 collagen in men. Age and body size were the strongest independent contributors to BMD and AHA. VAT was inversely associated with section modulus, cross‐sectional area, cross‐sectional moment of inertia in women, and hip axis length in men. Low bone turnover is associated with T2D and IR (in men), while BMD and hip strength/geometry are predominantly associated with body size. VAT, indicative of dysglycemia, is also associated with impaired bone geometry. Establishing the role of BTMs and AHA fracture risk may improve skeletal assessment in T2D people. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
- 8 June 2023
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 7 (9) , e10780
Open AccessAssociations of Type 2 Diabetes, Body Composition, and Insulin Resistance with Bone Parameters: The Dubbo Osteoporosis Epidemiology Study
Type 2 diabetes (T2D) may be associated with increased risk of fractures, despite preserved bone mineral density (BMD). Obesity and insulin resistance (IR) may have separate effects on bone turnover and bone strength, which contribute to skeletal fragility. We characterized and assessed the relative associations of obesity, body composition, IR, and T2D on bone turnover markers (BTMs), BMD, and advanced hip analysis (AHA). In this cross‐sectional analysis of Dubbo Osteoporosis Epidemiology Study, 525 (61.3% women) participants were grouped according to T2D, IR (homeostasis model assessment insulin resistance [HOMA‐IR] </≥2.5), and BMI (</≥25 kg/m2): insulin‐sensitive lean (IS‐L), insulin‐sensitive overweight/obese (IS‐O), insulin‐resistant (IR), and T2D. BMD, AHA, and body composition, including visceral adipose tissue (VAT) (on dual‐energy x‐ray absorptiometry scan) and fasting BTMs, were assessed. Analyses performed using Bayesian model averaging and principal component analysis. T2D was associated with low BTMs (by 26%–30% [95% confidence interval [CI] 11%–46%] in women, 35% [95% CI 18%–48%] in men compared to IS‐L), which persisted after adjustment for VAT. BTMs were similar among IR/IS‐O/IS‐L. BMD was similar among T2D/IR/IS‐O; BMD was low only in IS‐L. All groups were similar after adjustment for BMI. Similarly, AHA components were lowest in IS‐L (attenuated following adjustment). On multivariate analysis, T2D was independently associated with BTMs. IR was also associated with C‐terminal telopeptide of type 1 collagen in men. Age and body size were the strongest independent contributors to BMD and AHA. VAT was inversely associated with section modulus, cross‐sectional area, cross‐sectional moment of inertia in women, and hip axis length in men. Low bone turnover is associated with T2D and IR (in men), while BMD and hip strength/geometry are predominantly associated with body size. VAT, indicative of dysglycemia, is also associated with impaired bone geometry. Establishing the role of BTMs and AHA fracture risk may improve skeletal assessment in T2D people. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
- Open Access
- 19 March 2023
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 39 (5) , e3631
Factors associated with fragility fractures in type 2 diabetes: An analysis of the randomised controlled Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Aims: Fracture risk is elevated in some type 2 diabetes patients. Bone fragility may be associated with more clinically severe type 2 diabetes, although prospective studies are lacking. It is unknown which diabetes‐related characteristics are independently associated with fracture risk. In this post‐hoc analysis of fracture data from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial (ISRCTN#64783481), we hypothesised that diabetic microvascular complications are associated with bone fragility.Materials and Methods: The FIELD trial randomly assigned 9795 type 2 diabetes participants (aged 50–75 years) to receive oral co‐micronised fenofibrate 200 mg (n = 4895) or placebo (n = 4900) daily for a median of 5 years. We used Cox proportional hazards models to identify baseline sex‐specific diabetes‐related parameters independently associated with incident fractures.Results: Over 49,470 person‐years, 137/6138 men experienced 141 fractures and 143/3657 women experienced 145 fractures; incidence rates for the first fracture of 4∙4 (95% CI 3∙8–5∙2) and 7∙7 per 1000 person‐years (95% CI 6∙5–9∙1), respectively. Fenofibrate had no effect on fracture outcomes. In men, baseline macrovascular disease (HR 1∙52, 95% CI 1∙05–2∙21, p = 0∙03), insulin use (HR 1∙62, HR 1∙03–2∙55, p = 0∙03), and HDL‐cholesterol (HR 2∙20, 95% CI 1∙11–4∙36, p = 0∙02) were independently associated with fracture. In women, independent risk factors included baseline peripheral neuropathy (HR 2∙04, 95% CI 1∙16–3∙59, p = 0∙01) and insulin use (HR 1∙55, 95% CI 1∙02–2∙33, p = 0∙04).Conclusions: Insulin use and sex‐specific complications (in men, macrovascular disease; in women, neuropathy) are independently associated with fragility fractures in adults with type 2 diabetes.
- 19 March 2023
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 39 (5) , e3631
Open AccessFactors associated with fragility fractures in type 2 diabetes: An analysis of the randomised controlled Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Aims: Fracture risk is elevated in some type 2 diabetes patients. Bone fragility may be associated with more clinically severe type 2 diabetes, although prospective studies are lacking. It is unknown which diabetes‐related characteristics are independently associated with fracture risk. In this post‐hoc analysis of fracture data from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial (ISRCTN#64783481), we hypothesised that diabetic microvascular complications are associated with bone fragility.Materials and Methods: The FIELD trial randomly assigned 9795 type 2 diabetes participants (aged 50–75 years) to receive oral co‐micronised fenofibrate 200 mg (n = 4895) or placebo (n = 4900) daily for a median of 5 years. We used Cox proportional hazards models to identify baseline sex‐specific diabetes‐related parameters independently associated with incident fractures.Results: Over 49,470 person‐years, 137/6138 men experienced 141 fractures and 143/3657 women experienced 145 fractures; incidence rates for the first fracture of 4∙4 (95% CI 3∙8–5∙2) and 7∙7 per 1000 person‐years (95% CI 6∙5–9∙1), respectively. Fenofibrate had no effect on fracture outcomes. In men, baseline macrovascular disease (HR 1∙52, 95% CI 1∙05–2∙21, p = 0∙03), insulin use (HR 1∙62, HR 1∙03–2∙55, p = 0∙03), and HDL‐cholesterol (HR 2∙20, 95% CI 1∙11–4∙36, p = 0∙02) were independently associated with fracture. In women, independent risk factors included baseline peripheral neuropathy (HR 2∙04, 95% CI 1∙16–3∙59, p = 0∙01) and insulin use (HR 1∙55, 95% CI 1∙02–2∙33, p = 0∙04).Conclusions: Insulin use and sex‐specific complications (in men, macrovascular disease; in women, neuropathy) are independently associated with fragility fractures in adults with type 2 diabetes.
- 24 November 2022
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 34 (1) , 34-48
Contributors to impaired bone health in type 2 diabetes
- 24 November 2022
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 34 (1) , 34-48
Contributors to impaired bone health in type 2 diabetes
- Top Cited Papers
- 17 March 2022
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 33 (5) , 333-344
Assessment and treatment of osteoporosis and fractures in type 2 diabetes
- 17 March 2022
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 33 (5) , 333-344
Top Cited PapersAssessment and treatment of osteoporosis and fractures in type 2 diabetes